Notizie e Video - BAVARIAN NORDIC A/S [CBOE]

Weitere Videos findet Ihr unter: https://www.deraktionaer.tv Der Trading-Tipp des Tages ist diesmal Bavarian Nordic....

COPENHAGEN, Denmark, August 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first half of 2018 and releases its financial calendar for 2019. Positive RSV Phase 2 results recently confirmed the durability of broad vaccine responses after 1 year, which were rapidly increased following an annual booster vaccination. Compelling new research indicates a broader and more potent anti-tumor response after intra-tumoral...

Non-dilutive funding will support the construction and validation of a commercial fill-finish manufacturing facility for the Company's vaccines The Company upgrades its expectations to year end cash preparedness COPENHAGEN, Denmark, August 9, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the securing of a loan facility of EUR 30 million from the European Investment Bank (EIB), the long-term lending institution of the European Union owned by its Member States. The EIB's...

Broad antibody and T cell responses against RSV remained durable 1 year post a single vaccination with MVA-BN® RSV in the majority of subjects An annual booster of MVA-BN-RSV induced a broad and robust immune response, particularly in subjects with waning immunity one year after first vaccination, demonstrated by fast post-vaccination increases of neutralizing and total antibodies against both RSV subtypes (A & B); increases in mucosal RSV specific IgA and a broad, robust, and cellular immune...

Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors COPENHAGEN, Denmark, July 11, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb's checkpoint inhibitor, nivolumab (OPDIVO ® ), for the treatment of patients with resectable...

Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Globenewswire...

COPENHAGEN, Denmark, June 7, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 655,000 as a consequence of employees' exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 55,500 shares at DKK 73.90 and 10,000 shares at DKK 131.40....

COPENHAGEN, Denmark, May 31, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB, a fully integrated specialty pharmaceutical company listed on the Nasdaq Stockholm exchange, a role he has held since 2013. He plans to join Bavarian Nordic in the fourth quarter of 2018. Mr. Juuel comes to Bavarian Nordic with extensive experience in...

COPENHAGEN, Denmark, May 24, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first three months of 2018. First quarter highlights and subsequent events Positive results of the Phase 3 study of IMVAMUNE® were announced. The study, which compared the efficacy of IMVAMUNE with ACAM2000®, the current U.S. licensed replicating smallpox vaccine, met both of its primary efficacy endpoints. This was the second and final...

Phase 2 Study in Metastatic Chordoma to Initiate in second half of 2018 COPENHAGEN, Denmark, May 2, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's novel cancer vaccine BN-Brachyury for the treatment of chordoma. Chordoma is a rare type of cancer that develops along the spine, with presentation occurring at one of three main sites: sacrum, mobile spine, or the clivus (skull...

Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Globenewswire...

COPENHAGEN, Denmark, April 17, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows: The Annual Report for 2017 was adopted. The Board of Directors' proposal to transfer the Company's result to next year was also adopted. The General Meeting adopted a resolution to discharge the Board of Directors and the Board of Management from their obligations. The proposal to increase and extend the Board of Directors' authorization to increase...

COPENHAGEN, Denmark, 26 March, 2018 - Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on Tuesday, April 17, 2018 at 4 PM CET at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda: The Board of Directors' report on the Company's activities in the past year. Presentation of the Annual Report for adoption. A proposal from the Board of Directors...

Collaboration valued up to $36M Multivalent vaccine designed to protect humans against Eastern, Venezuelan, and Western equine encephalitis virus COPENHAGEN, Denmark, March 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the signing of a new alliance with the United States Department of Defense (DoD) for the development of a prophylactic vaccine against the equine encephalitis virus-a rare, but potentially deadly mosquito-borne illness. With funding from the DoD, Bavarian...

COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management. The Board of Directors of Bavarian Nordic A/S believes that restricted stock units as an incentive will further increase the long-term shared interests between the Executive Management and the Company's shareholders, Therefore, in accordance with the Company's remuneration policy and the general guidelines...

COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2017. Below is a summary of business progress, financial performance for the year and financial outlook for 2018 from the report. The full report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com . Key highlights in 2017 Our partnership with Janssen was expanded in July with additional worldwide license and collaboration agreements on...

Bavarian Nordic and Bristol-Myers Squibb agree to supply clinical material for the trial Investigator-led study represents the fourth clinical combination of CV301 with a checkpoint inhibitor COPENHAGEN, Denmark, March 8, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb's nivolumab (OPDIVO ® ) in patients with metastatic colorectal cancer (mCRC). CV301 is specifically designed...

Presence of antibodies in nasal mucosa suggest vaccine-induced immune protection at source of infection IgA antibodies against RSV observed in both serum and mucosa of vaccinated individuals COPENHAGEN, Denmark, March 6, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced additional positive data from its 421 patient, Phase 2 study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV in an older adult population. In a planned follow-up analysis,...

Third evaluation of CV301 in combination with a checkpoint inhibitor Multicenter investigator-sponsored trial to be led by Georgetown University COPENHAGEN, Denmark, February 26, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new collaboration that will investigate CV301, the Company's targeted immunotherapy candidate, and durvalumab (IMFINZI TM ), AstraZeneca's PD-L1 inhibitor, in combination with maintenance chemotherapy for patients with metastatic colorectal or...

Study successfully achieved both primary endpoints Second positive Phase 3 demonstrating the safety and efficacy of IMVAMUNE and final study required for licensure, as agreed with FDA BLA filing expected in second half of 2018 with fast track designation COPENHAGEN, Denmark, February 6, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE ® . The study achieved both of...